Here, after all, we find a laundry list of salient risks: disclosure of confidential business information, reduced employee productivity, negative remarks by current and former employees, damaging remarks about competitors, etc.

FORBES: The Clairvoyant Corporation: General Counsel as Supermen

In fact, in an accompanying editorial, The Street columnist Adam Feuerstein and Mark Ratain of the University of Chicago calculated market caps at 120 days before public disclosure and found that values were 80-fold greater for those with positive results than those with negative trials.

FORBES: Why Pharma Stocks May Rise Before Trial Data Is Released